PL3675853T3 - Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego - Google Patents

Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego

Info

Publication number
PL3675853T3
PL3675853T3 PL18766482.6T PL18766482T PL3675853T3 PL 3675853 T3 PL3675853 T3 PL 3675853T3 PL 18766482 T PL18766482 T PL 18766482T PL 3675853 T3 PL3675853 T3 PL 3675853T3
Authority
PL
Poland
Prior art keywords
patients
enhancing
methods
cardiac function
fabry disease
Prior art date
Application number
PL18766482.6T
Other languages
English (en)
Inventor
Jeff Castelli
Jay Barth
Nina SKUBAN
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3675853(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of PL3675853T3 publication Critical patent/PL3675853T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18766482.6T 2017-08-28 2018-08-28 Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego PL3675853T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
PCT/US2018/048257 WO2019046244A1 (en) 2017-08-28 2018-08-28 METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE

Publications (1)

Publication Number Publication Date
PL3675853T3 true PL3675853T3 (pl) 2022-12-27

Family

ID=63528948

Family Applications (2)

Application Number Title Priority Date Filing Date
PL22194251.9T PL4176877T3 (pl) 2017-08-28 2018-08-28 Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego
PL18766482.6T PL3675853T3 (pl) 2017-08-28 2018-08-28 Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL22194251.9T PL4176877T3 (pl) 2017-08-28 2018-08-28 Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego

Country Status (26)

Country Link
US (1) US20200222377A1 (pl)
EP (3) EP3675853B1 (pl)
JP (3) JP7755929B2 (pl)
KR (2) KR102790184B1 (pl)
CN (1) CN111770753A (pl)
AR (1) AR112482A1 (pl)
AU (2) AU2018326364B2 (pl)
CA (1) CA3074450C (pl)
CL (1) CL2020000491A1 (pl)
DK (2) DK4176877T3 (pl)
EA (1) EA202090564A1 (pl)
ES (2) ES2931054T3 (pl)
FI (1) FI4176877T3 (pl)
HR (2) HRP20250064T1 (pl)
HU (2) HUE070433T2 (pl)
IL (3) IL272893B2 (pl)
LT (2) LT4176877T (pl)
MX (2) MX2020002229A (pl)
PL (2) PL4176877T3 (pl)
PT (2) PT4176877T (pl)
RS (2) RS66515B1 (pl)
SG (1) SG11202001707PA (pl)
SI (1) SI4176877T1 (pl)
SM (2) SMT202500073T1 (pl)
TW (1) TWI845479B (pl)
WO (1) WO2019046244A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) * 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
US10811814B2 (en) 2017-08-28 2020-10-20 John Mezzalingua Associates, LLC Weather protecting (WP) housing for coaxial cable connectors

Also Published As

Publication number Publication date
IL272893B2 (en) 2024-07-01
CN111770753A (zh) 2020-10-13
HUE060287T2 (hu) 2023-02-28
SG11202001707PA (en) 2020-03-30
HUE070433T2 (hu) 2025-06-28
FI4176877T3 (fi) 2025-03-06
PT3675853T (pt) 2022-11-28
PL4176877T3 (pl) 2025-04-07
EP4176877B1 (en) 2024-12-04
CL2020000491A1 (es) 2020-09-11
EP4176877A1 (en) 2023-05-10
CA3074450C (en) 2024-10-01
DK3675853T3 (da) 2022-11-28
IL310648A (en) 2024-04-01
WO2019046244A1 (en) 2019-03-07
EP3675853B1 (en) 2022-09-07
RS63742B1 (sr) 2022-12-30
SMT202200459T1 (it) 2023-01-13
RS66515B1 (sr) 2025-03-31
JP7755929B2 (ja) 2025-10-17
BR112020003974A2 (pt) 2020-09-01
IL272893B1 (en) 2024-03-01
EP4588476A1 (en) 2025-07-23
IL324182A (en) 2025-12-01
EA202090564A1 (ru) 2020-06-15
KR20200044908A (ko) 2020-04-29
TW201919619A (zh) 2019-06-01
DK4176877T3 (da) 2025-02-24
IL272893A (en) 2020-04-30
SI4176877T1 (sl) 2025-03-31
CA3074450A1 (en) 2019-03-07
TWI845479B (zh) 2024-06-21
KR20250049561A (ko) 2025-04-11
KR102790184B1 (ko) 2025-04-01
HRP20221366T1 (hr) 2023-01-06
EP3675853A1 (en) 2020-07-08
HRP20250064T1 (hr) 2025-03-14
PT4176877T (pt) 2025-02-24
JP2020531550A (ja) 2020-11-05
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
US20200222377A1 (en) 2020-07-16
ES3013820T3 (en) 2025-04-15
LT4176877T (lt) 2025-02-10
MX2020002229A (es) 2020-07-20
AU2024266945A1 (en) 2024-12-19
JP2025138638A (ja) 2025-09-25
AU2018326364A1 (en) 2020-04-09
LT3675853T (lt) 2022-12-12
JP2023051998A (ja) 2023-04-11
AU2018326364B2 (en) 2024-08-29
AR112482A1 (es) 2019-10-30
ES2931054T3 (es) 2022-12-23

Similar Documents

Publication Publication Date Title
IL272893A (en) Methods for increasing and/or stabilizing cardiac functions in patients with Fabry disease
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
IL253351A0 (en) Cardiac stimulation of conduction pathways between the atria and ventricles and of tissues associated with these pathways
IL249580A0 (en) Methods for anesthetizing nerve tissue in the trigeminal nerve pathway and their medical uses
EP3319683A4 (en) Implantable nerve stimulator having internal electronics without asic and methods of use
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
IL269083A (en) Methods for preventing and treating heart disease
MA50358A (fr) Sémaglutide en thérapie médicale
HUE064761T2 (hu) Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
GB201709840D0 (en) Methods and medical uses
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
ITUA20163417A1 (it) Fat and medical uses thereof
IL274773B1 (en) A pyrimidine sulfamide derivative and a method of its preparation and medical application
EP3681410A4 (en) HEART TREATMENT SYSTEM AND METHOD
EP3644753A4 (en) METHODS FOR MAINTAINING AND IMPROVING RENAL FUNCTION IN PATIENTS WITH RENAL DISEASE AND STANDARD TREATMENT THERAPY
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
HUE069934T2 (hu) A migalasztát alkalmazása agy-érrendszeri esemény kockázatának csökkentésére fabry-betegségben szenvedõ betegeknél
HK40029560A (en) Methods and medical uses relating to the treatment of hypoglycaemia
Thongcharoen Acharn Dr. Somchai-A Good Person of Thai and Global Academic Societies
GB201806133D0 (en) Methods and medical uses
GB201709837D0 (en) Methods and medical uses
EP3288562A4 (en) Method for improving kidney and/or heart function in patients with kidney disease